New Research on Osteoarthritis Treatment

Overview of Osteoarthritis

Recent findings published in the *Annals of the Rheumatic Diseases* indicate that a specific blocker may effectively halt the progression of osteoarthritis in the knee when injected into affected joints. Osteoarthritis is recognized as the most prevalent form of arthritis, characterized by chronic joint pain and the degradation of cartilage, leading to excessive bone growth. Typically, this condition begins in the smaller joints of the hands and feet before advancing to larger joints such as the elbows, knees, shoulders, and hips.

The Impact of Osteoarthritis in Canada

Osteoarthritis stands as a primary cause of disability in Canada, with over 4.6 million Canadians currently affected, according to Bone and Joint Canada. Key risk factors for developing osteoarthritis include advancing age, genetic predisposition, repeated joint injuries, and obesity. At present, no definitive cure exists for this condition. Available treatments primarily focus on alleviating pain, minimizing joint stress, and enhancing muscle strength to support affected joints.

Breakthrough Treatment Using Locked Nucleic Acid

Research Development

A team of researchers from the University of Toronto has embarked on a promising new therapeutic approach that may significantly inhibit knee joint degeneration. This innovative treatment leverages antisense technology to block the harmful effects of a specific microRNA.

Key Findings

Utilizing both animal models and human tissue samples from patients at Toronto Western Hospital with knee and/or spine osteoarthritis, the study identified a biomarker known as microRNA-181a-5p, which plays a critical role in inflammation, cartilage degradation, and collagen loss. The research team demonstrated that an intra-articular injection of in vivo grade locked nucleic acid targeting microRNA-181a-5p could reduce cartilage degeneration in both the facet joint and knee.

Future Implications

This groundbreaking study paves the way for the potential redefinition of osteoarthritis treatment. However, further investigation is necessary to fully understand the associated risks and long-term benefits of this novel approach.

Reference

Nakamura, A. et al. microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints. *Annals of the Rheumatic Diseases*. Published Online First: 04 October 2018. DOI: 10.1136/annrheumdis-2018-213629.